Lithuania vs Singapore: Hepatitis B surface antigen (HBsAg) prevalence
Lithuania
0.1%
in 2024
Singapore
0.1%
in 2024
Lithuania rank
101st
Singapore rank
101st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Lithuania
- Singapore
How they compare
Lithuania currently reports 0.1% against 0.1% in Singapore, a difference of 0.0%.
Across all 10 years both countries report, Singapore has been ahead every year.
Lithuania ranks 101st and Singapore ranks 101st of 194 countries.
Singapore has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Singapore |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Lithuania or Singapore?
- Lithuania, at 0.1% against 0.1% in Singapore as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Lithuania and Singapore?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Singapore?
- 10 years are reported by both, from 2015 to 2024.
- How do Lithuania and Singapore rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Lithuania ranks 101st and Singapore ranks 101st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.